Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1072-1082. doi: 10.1051/medsci/2019242. Epub 2020 Jan 6.

[Bispecific antibodies, novel therapeutic candidates harnessing the immune system].

[Article in French; Abstract available in French from the publisher]

Author information

1
Aix Marseille Univ, CNRS, Inserm, Institut Paoli-Calmettes, CRCM, Marseille, France.
2
Centre d'Innovation Thérapeutique en Oncologie - Servier, F78290 Croissy-sur-Seine, France.

Abstract

in English, French

Over the past ten years, an increased knowledge of tumor biology and immunology allowed the design and development of novel therapeutic antibody and protein scaffold formats, where bispecific antibodies (Abs) play a major role. The latter molecules can (1) bring novel pharmacological properties through the co-engagement of two targets, (2) increase the safety profile as compared to a combination of two antibodies thanks to a targeted relocation to the tumor and (3) reduce development and manufacturing costs associated with single drug product. This review analyzes the different bispecific antibodies and scaffolds described in the field of immuno-oncology, their structure and major pharmacological and physico-chemical properties.

PMID:
31903920
DOI:
10.1051/medsci/2019242

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center